The Macular Edema drugs in development market research report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Macular Edema. Buy the report here.

Smarter leaders trust GlobalData


Data Insights N

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Macular Edema and features dormant and discontinued products.

GlobalData tracks 168 drugs in development for Macular Edema by 138 companies/universities/institutes. The top development phase for Macular Edema is preclinical with 82 drugs in that stage. The Macular Edema pipeline has 165 drugs in development by companies and three by universities/ institutes. Some of the companies in the Macular Edema pipeline products market are: F. Hoffmann-La Roche, AffaMed Therapeutics US and ANBITION.

The key targets in the Macular Edema pipeline products market include Vascular Endothelial Growth Factor (VEGF) , Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA), and Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF).

The key mechanisms of action in the Macular Edema pipeline product include Vascular Endothelial Growth Factor (VEGF) Inhibitor with 35 drugs in Phase III. The Macular Edema pipeline products include 14 routes of administration with the top ROA being Intravitreal and 14 key molecule types in the Macular Edema pipeline products market including Monoclonal Antibody, and Small Molecule.

Macular Edema overview

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, the side effects of certain medications, and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

For a complete picture of Macular Edema’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.